Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative Study

Kaczorowski-Worthley A, Mudaranthakam DP, Reichuber J, Streiler C, Pandya S, Boente R, Mathai SK, Adegunsoye A, Swigris J, Volkmann ER, Solomon JJ, England BR, Matson[...]

Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials

Ahmed M, Zulfiqar E, Ashraf H, Hashmi TM, Ahmed R, Rana JS, Greene SJ, Mentz RJ, Fudim M, Fonarow GC. Reduced-dose vs full-dose direct oral[...]

Provider Attitudes and Perceptions on Using Artificial Intelligence in Colonoscopy: A Systematic Review and Meta-Analysis

Soleymanjahi S, Rajashekar N, Chung S, Grimshaw AA, Tvedt MJK, Foroutan F, Sultan S, Shung DL, Kolb JM. Provider Attitudes and Perceptions on Using Artificial[...]